Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-386 in Dyslipidemia Patients With Hypertension
NCT04312698Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of telmisartan, rosuvastatin, ezetimibe in dyslipidemia, hypertension (HTN), sponsored by Chong Kun Dang Holdings. Started Aug 2019; status: completed.
02
Drugs
telmisartanrosuvastatinezetimibe
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT04312698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312698.